Precipio Inc (PRPO)
NASDAQ:PRPO
Top Page
Precipio
(NASDAQ:PRPO)
Select Model
Select Model
Rating:57Neutral
Price Target:
$29.00
▲(25.60% Upside)
Action:ReiteratedDate:04/08/26
The score is driven primarily by improving fundamentals (revenue growth and cash flow turning positive) but tempered by financial-statement quality/consistency concerns and still-weak profitability durability. Technicals are supportive with price above major moving averages and positive MACD. Valuation is a drag due to a negative P/E and no dividend yield, while the latest earnings call was broadly constructive but flagged meaningful Products execution and margin-volatility risks.
Positive Factors
Sustained revenue growth (30% YoY in 2025)
A 30% revenue increase to $24M in 2025 indicates durable demand expansion for core diagnostic services. Consistent top-line growth supports scale benefits, raises operating leverage potential, and provides a firmer base to invest in commercial expansion and product commercialization over the next 2–5 years.
Negative Factors
Earnings‑quality & reporting transparency concerns
Zeroed gross/operating profit fields and declining total assets reduce confidence in financial statement continuity and comparability. Persistent negative ROE and past asset erosion complicate assessment of sustainable profitability, increasing the risk that reported improvements may mask accounting or timing distortions.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth (30% YoY in 2025)
A 30% revenue increase to $24M in 2025 indicates durable demand expansion for core diagnostic services. Consistent top-line growth supports scale benefits, raises operating leverage potential, and provides a firmer base to invest in commercial expansion and product commercialization over the next 2–5 years.
Read all positive factors
Precipio (PRPO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.76M
Dividend YieldN/A
Average Volume (3M)19.92K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth30.95%
EPS Growth59.67%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.29
Shares Outstanding1,783,682
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda32.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Precipio Business Overview & Revenue Model
Company Description
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enab...
How the Company Makes Money
Precipio makes money primarily by performing and billing for diagnostic laboratory tests delivered through its clinical lab operations. Revenue is generated when clinicians order the company’s tests for patients; Precipio then processes specimens ...
Precipio Earnings Call Summary
Earnings Call Date:Apr 06, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Positive
The call communicates a generally positive trajectory: the company reached a key inflection to positive cash flow, delivered 30% revenue growth to $24M, improved overall gross margin from 41% to 45%, strengthened the commercial organization, and demonstrated product manufacturing scalability and clinical validation. Key challenges remain in the Products division—revenue growth was muted by customer operational interruptions, earlier under-resourced commercial coverage, onboarding timing and margin volatility driven by one-time production effects. Management presented concrete mitigations (new hires, backup lab arrangements, distributor strategy) and a clear growth focus for 2026, so the balance of developments is favorable but with identifiable execution risks to monitor.Positive Updates
Revenue Growth and Scale
Fiscal year 2025 revenue of $24.0M, representing +30% year-over-year growth, driven primarily by Pathology Services and increased demand for specialized diagnostic and molecular testing.
Negative Updates
Products Revenue Underperformance
Products division revenues did not grow as expected in 2025; growth was muted by customer operational pauses (machine downtime, staffing/maternity relief) and timing delays in customer onboarding, offsetting gains from new customers.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth and Scale
Fiscal year 2025 revenue of $24.0M, representing +30% year-over-year growth, driven primarily by Pathology Services and increased demand for specialized diagnostic and molecular testing.
Read all positive updates
Company Guidance
Management guided that Precipio moved to positive cash flow in 2025 after delivering $24.0M of revenue (up 30% YoY) and improving consolidated gross margin to 45% (from 41% in 2024); noted product gross margins swung from ~30% in Q3 to an unusually high 90% in Q4 (historical product baseline ~40–50%) due to concentrated production to cover an anticipated 2–4 week Q1 2026 downtime; confirmed repayment of the Change Healthcare loan and exercise of all remaining warrants, 50+ investor interactions amid ~300% share‑price appreciation in 2025, hiring in January 2026 of a full commercial team (CCO + 2 BDOs, up from essentially one rep), plans to reinvest pathology‑generated cash into scaling products across an estimated $500M U.S. addressable market, a targeted shift of revenue mix from ~90/10 services/products toward a more balanced split over 3–5 years, and a productized service offering to deliver next‑day AML results with a comprehensive 5‑day follow‑up.Precipio Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 24.05M | 15.96M | 15.20M | 9.41M | 8.85M |
| Gross Profit | 10.71M | 7.56M | 6.02M | 2.51M | 2.39M |
| EBITDA | 1.46M | -2.70M | -6.31M | -10.65M | -7.05M |
| Net Income | -363.00K | -4.29M | -5.85M | -12.20M | -8.55M |
Balance Sheet | |||||
| Total Assets | 21.32M | 17.00M | 18.10M | 21.50M | 30.44M |
| Cash, Cash Equivalents and Short-Term Investments | 6.04M | 1.39M | 1.50M | 3.44M | 11.67M |
| Total Debt | 3.65M | 1.25M | 1.12M | 1.39M | 1.43M |
| Total Liabilities | 6.76M | 4.90M | 3.67M | 5.14M | 5.83M |
| Stockholders Equity | 14.56M | 12.09M | 14.43M | 16.30M | 24.56M |
Cash Flow | |||||
| Free Cash Flow | 359.00K | 216.00K | -3.69M | -8.00M | -7.26M |
| Operating Cash Flow | 685.00K | 439.00K | -3.56M | -7.72M | -6.58M |
| Investing Cash Flow | -326.00K | -223.00K | -126.00K | -277.00K | -682.00K |
| Financing Cash Flow | 903.00K | -329.00K | 1.74M | -225.00K | 16.27M |
Precipio Technical Analysis
Positive
23.09
Price Trends
25.10
Positive
24.43
Positive
20.52
Positive
Market Momentum
0.32
Negative
56.85
Neutral
71.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Positive. The current price of 23.09 is below the 20-day moving average (MA) of 26.93, below the 50-day MA of 25.10, and above the 200-day MA of 20.52, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 71.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRPO.
Precipio Risk Analysis
Precipio disclosed 62 risk factors in its most recent earnings report. Precipio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precipio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $49.76M | -101.61 | -10.07% | ― | 30.95% | 59.67% | |
53 Neutral | $17.63M | -0.14 | -245.18% | ― | -27.66% | 13.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $13.09M | -0.32 | -56.22% | ― | -13.84% | 88.80% | |
46 Neutral | $11.26M | -0.95 | 80.66% | ― | -4.35% | -6.31% | |
46 Neutral | $49.79M | -13.54 | 88.02% | ― | 7.29% | 7.24% | |
44 Neutral | $5.30M | -0.85 | -197.93% | ― | 3.26% | 65.96% |
* Healthcare Sector Average
PRPO
Precipio
27.90
22.21
390.33%
TRIB
Trinity Biotech
0.60
0.04
7.09%
DRIO
DarioHealth
6.82
-4.54
-39.96%
BNGO
BioNano Genomics
1.18
-1.90
-61.69%
INBS
Intelligent Bio Solutions
2.65
-9.65
-78.46%
BIAF
bioAffinity Technologies, Inc.
3.92
-14.85
-79.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.